Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195) Financial Results:
Biocon Ltd Q2FY25; 84% fall in Profits
Categories
Biotechnology
Sarthak Metals ventures into Biotechnology: Driving Innovation and Sustainable Growth
Introduction Sarthak Metals Limited (SMLT) has ventured into the biotechnology sector, focusing on areas that leverage living organisms and their derivatives to
Praj Industries Ltd Q4FY24; 5% rise in Profits
Praj Industries Ltd., founded in 1983 is a leading biotechnology and engineering company globally. It offers sustainable solutions in bioenergy, water purification,
Rossari Biotech Ltd Q4FY24; 17% rise in Profits
Rossari Biotech was started in 2003. They are among the largest manufacturers of textile specialty chemicals in India. Financial Results: Rossari Biotech
Laurus Labs Ltd Q4 FY24 Earnings Conference Call Insights
Key highlights from Laurus Labs Ltd (LAURUSLABS) Q4 FY24 Earnings Concall R&D Progress Advanced several pipeline projects across offerings and augmented technology/manufacturing
Laurus Labs Ltd Q4FY24; 29% fall in Profits
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients
Wockhardt Ltd Q3FY24; 0% rise in Revenue
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).
Laurus Labs Ltd Q3FY24; 89% fall in Profits
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients
Syngene International Ltd Q3FY24; 2% rise in Profits
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated
Laurus Labs Limited Q3 FY24 Earnings Conference Call Insights
Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY24 Earnings Concall Business Performance Gross margins remained resilient at over 52% for several
Laurus Labs Limited Q2 FY24 Earnings Conference Call Insights
Key highlights from Laurus Labs Limited (LAURUSLABS) Q2 FY24 Earnings Concall Q2 FY24 Results Revenue declined 22% year-on-year to INR1,224 crores.. EBITDA
Syngene International Ltd Q2FY24; 14% rise in Profits
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated
Wockhardt Ltd Q1FY24; 8% rise in Revenue
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).
Shilpa Medicare Ltd Q1FY24; 50% fall in Profits
Shilpa Medicare is engaged in the business of high quality Active Pharmaceuticals Ingredients (APIs), Intermediates, Formulations, New Drug delivery system, Peptides, Biotech
Panacea Biotec Q4FY23 Earnings Story
Panacea Biotec was set up in the year 1984, under the name of Panacea Drugs Private Limited and was publicly listed in
Panacea Biotec Q4FY23; 8% Fall in Revenues
Panacea Biotec Ltd.’s revenue in Q4FY23 rose 13% to ₹ 12,557 crores. Consolidated Profit After Tax came at ₹ 4,320 crores in
Laurus Labs Limited Q4 FY23 Earnings Conference Call Insights
https://youtu.be/5Vtl-XMN8qg Key highlights from Laurus Labs Limited (LAURUSLABS) Q4 FY23 Earnings Concall Management Update: [00:09:24]LAURUSLABS said it invested in expanding non-ARV formulation
Laurus Labs Limited Q3 FY23 Earnings Conference Call Insights
Key highlights from Laurus Labs Limited (LAURUSLABS) Q3 FY23 Earnings Concall Management Update: [00:03:57] LAURUSLABS said its strong results were driven by
Syngene International Ltd (SYNGENE) Q3 FY23 Earnings Concall Transcript
Syngene International Ltd (NSE: SYNGENE) Q3 FY23 Earnings Concall dated Jan. 24, 2023 Corporate Participants: Avantika Mishra -- Associate - EY Jonathan Hunt -- Managing Director
Syngene reported a 5% rise in its net profit for Q3FY23
Syngene International reported a 5.5% rise in consolidated net profit to INR 109.70 crore in Q3 FY23 as against INR104 crore posted
Syngene International Ltd (SYNGENE) Q3 FY23 Earnings Concall Transcript
Syngene International Ltd (NSE: SYNGENE) Q3 FY23 Earnings Concall dated January 24, 2023 Corporate Participants: Avantika Mishra -- Associate - EY Jonathan Hunt -- Managing Director